We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Guideline: Extended Survival Is Endpoint in PAH Trials
Guideline: Extended Survival Is Endpoint in PAH Trials
February 4, 2009
Sponsors of pulmonary arterial hypertension (PAH) drug trials should consider goals that prolong patient survival, reduce morbidity, ease symptoms and improve quality of life, a European Medicines Agency (EMEA) draft guideline says.